<DOC>
	<DOCNO>NCT01357941</DOCNO>
	<brief_summary>Pregnant woman prior history venous thromboembolism ( VTE ) increase risk recurrent VTE . Current guideline assess role prophylaxis pregnant woman prior VTE base primarily expert opinion optimal clinical management strategy remain unclear . This multicentre , prospective cohort study aim test follow hypothesis : 1 . Antepartum prophylaxis fixed-dose low molecular-weight heparin ( LMWH ) safe , convenient associate acceptably low risk recurrent VTE woman single prior episode VTE either unprovoked associate minor transient risk factor . ( Moderate risk cohort ) 2 . Withholding antepartum prophylaxis safe ( recurrence risk &lt; 1 % ) pregnant woman single prior episode VTE provoke major transient risk factor . ( Low risk cohort ) All study patient receive 6 week postpartum prophylaxis .</brief_summary>
	<brief_title>Need Antepartum Thromboprophylaxis Pregnant Women With One Prior Episode Venous Thromboembolism ( VTE )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>Confirmed pregnancy ( positive serum urine ) At least 18 year age History one prior episode VTE consist DVT ( diagnose compression ultrasonography [ CUS ] venography ) and/or PE ( diagnose ventilationperfusion [ V/Q ] lung scintigraphy , compute tomographic pulmonary angiography [ CTPA ] , traditional pulmonary angiography ) Ongoing need therapeutic anticoagulation prevention treatment cardioembolic stroke Known highrisk thrombophilia ( specifically antithrombin deficiency , protein S deficiency , protein C deficiency , homozygosity factor V Leiden prothrombin G20210A mutation , antiphospholipid antibody compound abnormality ) VTE within 3 month current pregnancy Clinical risk factor initial episode VTE , present , resolve ( exclude pregnancy ) Known contraindication anticoagulation ( include active , uncontrolled bleed major bleed within previous 4 week ) For patient prior unprovoked VTE , contraindication LMWH ( include allergy , HIT , impair renal function , osteoporosis ) Geographic social factor preclude followup Inability unwillingness provide inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>venous thromboembolism</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>thromboprophylaxis</keyword>
	<keyword>thrombosis</keyword>
	<keyword>embolism thrombosis</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>venous thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>hematologic agent</keyword>
	<keyword>cardiovascular agent</keyword>
	<keyword>enoxaparin</keyword>
	<keyword>dalteparin</keyword>
	<keyword>tinzaparin</keyword>
	<keyword>pregnancy complication</keyword>
</DOC>